Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-Bevacizumab
IHG was more frequently associated with MASLD-HCC compared to controls, confirming preclinical data and suggesting biological differences between tumors, with potential implications for future research. MASLD should not be seen as a contraindication to immunotherapy.
Authors
- Luca Ielasi (ORCID: https://orcid.org/0000-0003-4162-2319)
- Leonardo Stella (ORCID: https://orcid.org/0000-0002-3431-0803)
- Tiziana Pressiani (ORCID: https://orcid.org/0000-0001-6919-1536)
- Stefania De Lorenzo (ORCID: https://orcid.org/0000-0002-4866-4864)
- Francesco Tovoli (ORCID: https://orcid.org/0000-0002-8350-1155)
- Gianluca Svegliati‐Baroni (ORCID: https://orcid.org/0000-0003-4399-3359)
- Ciro Celsa (ORCID: https://orcid.org/0000-0002-5662-2162)
- Giuseppe Cabibbo (ORCID: https://orcid.org/0000-0002-0946-3859)
- Alessandro Granito (ORCID: https://orcid.org/0000-0002-0637-739X)
- Piera Federico (ORCID: https://orcid.org/0000-0002-0863-7546)
- Benedetta Stefanini (ORCID: https://orcid.org/0000-0003-2470-7230)
- Fabio Piscaglia (ORCID: https://orcid.org/0000-0001-8264-1845)
- Caterina Vivaldi (ORCID: https://orcid.org/0000-0001-9307-2326)
- Andrea Palloni (ORCID: https://orcid.org/0000-0003-1260-2765)
- Claudia Campani (ORCID: https://orcid.org/0000-0003-3842-782X)
- Sara Lonardi (ORCID: https://orcid.org/0000-0002-7593-8138)
- Mariangela Bruccoleri (ORCID: https://orcid.org/0000-0001-7400-4854)
- Maria Boe
- Gianluca Masi (ORCID: https://orcid.org/0000-0001-8329-8989)
- Bruno Daniele (ORCID: https://orcid.org/0000-0002-2638-3156)
- Rusi Chen
- Francesca Romana Ponziani (ORCID: https://orcid.org/0000-0002-5924-6238)
- Lorenza Rimassa (ORCID: https://orcid.org/0000-0001-9957-3615)
- Caterina Soldà (ORCID: https://orcid.org/0000-0002-2914-6674)
- Giovanni Brandi (ORCID: https://orcid.org/0000-0003-0013-2858)
- Ingrid Garajová (ORCID: https://orcid.org/0000-0002-9302-6896)
- Bernardo Stefanini (ORCID: https://orcid.org/0000-0003-3800-5678)
- Fabio Marra (ORCID: https://orcid.org/0000-0001-8629-0878)
- Massimo Alberto Iavarone (ORCID: https://orcid.org/0000-0003-3493-6504)
- Lorenzo Lani (ORCID: https://orcid.org/0000-0001-5133-5829)
- Andrea Dalbeni (ORCID: https://orcid.org/0000-0003-0402-4176)
- Alessandra Auriemma
Institutions
- Università Cattolica del Sacro Cuore (IT)
- University of Verona (IT)
- Marche Polytechnic University (IT)
- University of Parma (IT)
- Humanitas University (IT)
- University of Milan (IT)
- Agostino Gemelli University Polyclinic (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Ospedale Maggiore (IT)
- Istituto Oncologico Veneto (IT)
- Centro Clinico Nemo (IT)
- Azienda USL di Bologna (IT)
- Ospedale per gli Infermi (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- IRCCS Humanitas Research Hospital (IT)
- Azienda Ospedaliera Universitaria Pisana (IT)
- University of Florence (IT)
- University of Palermo (IT)
- University of Bologna (IT)
Publication Details
- Journal
- Liver Cancer
- Published
- 2025-05-26
- DOI
- https://doi.org/10.1159/000545494
- Citations
- 2
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Università degli Studi di Palermo
- Università di Bologna
- Università degli Studi di Verona